Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/29884
Title: | Effects of sacubitril/valsartan on functional status and exercise capacity in real-world patients | Authors: | Lau, Chirik Wah MARTENS, Pieter Lambeets, Seppe DUPONT, Matthias MULLENS, Wilfried |
Issue Date: | 2019 | Publisher: | TAYLOR & FRANCIS LTD | Source: | ACTA CARDIOLOGICA, 74(5), p. 405-412 | Abstract: | Background: Sacubitril/valsartan significantly reduced heart failure(HF) hospitalisations and mortality in the PARADIGM-HF-trial. However real-world data on symptomatic and functional improvement are lacking. Methods: Between December 2016 and January 2018, we retrospectively collected baseline and follow-up data including New York Heart Association (NYHA)-functional class and Cardio-pulmonary exercise data(CPET) in all HF-patients receiving sacubitril/valsartan. Additionally, in patients with an implantable electric cardiovascular device (IECD) enrolled in remote telemonitoring, we quantified patient level activity before and after initiation. Results: A total of 201 patients (82% males) were identified. NYHA-functional class was reassessed after an average of 221 +/- 114 days. Overall, 3.3% of patients improved 2 NYHA classes, 28.7% improved 1 NYHA class, 64% remained stable and 4% deteriorated 1 NYHA class. Patients with symptomatic improvement exhibited a larger reduction in Left Ventricular End Systolic Volume(LVESV) and a larger increase in Left Ventricular Ejection Fraction(LVEF[p-value both <.05]). In total, 110 patients (55%) were equipped with an IECD capable of quantifying outpatient activity-level. On an average of 364 days before sacubitril/valsartan, an activity expressed as %-of-the-day was 13 +/- 2%, vs. 18 +/- 3% the 364 days following sacubitril/valsartan initiation. Signifying a 38% improvement in the out-patient activity level. CPET-data was obtained in paired-fashion in 45 patients (22%). VO2max at baseline (14.7 +/- 3.8 mL/kg/min) did not significantly change at follow-up (14.1 +/- 4.7 mL/min/kg; p = .237). Conclusion: Real-world patients exhibit significant symptomatic and functional improvement following the initiation of sacubitril/valsartan. However, larger prospective studies are necessary to assess the impact of sacubitril/valsartan on indices of maximal exercise performance measured during CPET. | Notes: | [Lau, Chirik Wah; Martens, Pieter; Lambeets, Seppe; Dupont, Matthias; Mullens, Wilfried] Ziekenhuis Oost Limburg, Dept Cardiol, Schiepse Bos 6, B-3600 Genk, Belgium. [Martens, Pieter] Hasselt Univ, Doctoral Sch Med & Life Sci, Diepenbeek, Belgium. [Mullens, Wilfried] Hasselt Univ, Fac Med & Life Sci, Biomed Res Inst, Diepenbeek, Belgium. | Keywords: | Sacubitril/valsartan; cardiopulmonary exercise test; NYHA functional class; functionality; real world;Sacubitril; valsartan; cardiopulmonary exercise test; NYHA functional class; functionality; real world | Document URI: | http://hdl.handle.net/1942/29884 | ISSN: | 0001-5385 | e-ISSN: | 1784-973X | DOI: | 10.1080/00015385.2018.1521054 | ISI #: | 000487298100006 | Rights: | 2018 Belgian Society of Cardiology | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2020 |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
lau2018.pdf Restricted Access | Published version | 1.02 MB | Adobe PDF | View/Open Request a copy |
SCOPUSTM
Citations
4
checked on Sep 2, 2020
WEB OF SCIENCETM
Citations
18
checked on Oct 14, 2024
Page view(s)
112
checked on Jul 22, 2022
Download(s)
102
checked on Jul 22, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.